Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 4/20 | 0.52 |
| ▸ | CA9 | Q16790 | 4/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | JUN | P05412 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7053382 | 0.84 | TRIM24 (0.57) | CYP1A1CYP1A2CYP1B1MAPTALDH1A1 | |
| SCHEMBL30380928 | 0.83 | MIF (0.61) | CYP1A1CYP1A2CYP1B1CA12CA9 | |
| SCHEMBL1920580 | 0.83 | MIF (0.61) | CYP1A1CYP1A2CYP1B1CA12CA9 | |
| SCHEMBL1920579 | 0.83 | MIF (0.61) | CYP1A1CYP1A2CYP1B1CA12CA9 | |
| SCHEMBL15239140 | 0.83 | MIF (0.61) | CYP1A1CYP1A2CYP1B1CA12CA9 | |
| SCHEMBL29090933 | 0.83 | CYP1A1 (0.58) | CYP1A1CYP1A2CYP1B1CA12CA9 | |
| SCHEMBL22398305 | 0.82 | CA12 (0.57) | CYP1A1CYP1A2CYP1B1CA12CA9 | |
| SCHEMBL30632936 | 0.82 | CA12 (0.57) | CYP1A1CYP1A2CYP1B1CA12CA9 | |
| SCHEMBL19972316 | 0.82 | CA12 (0.57) | CYP1A1CYP1A2CYP1B1CA12CA9 | |
| SCHEMBL14272842 | 0.82 | CA12 (0.57) | CYP1A1CYP1A2CYP1B1CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2004110351-A2 | HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | CYP1A1 83/4885CYP1A2 47/4885CYP1B1 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.